Clinical decisions in Hepatology: The pirfenidone case analysis

Annals of Hepatology

Volumn 13, Issue 2, 2014, Pages 163-165

  Chavez Tapia, Norberto C ^a   Méndez Sánchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; EVIDENCE BASED PRACTICE; HUMAN; LIVER FIBROSIS; META ANALYSIS (TOPIC); PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG APPROVAL; HUMANS; LIVER CIRRHOSIS; MEXICO; PYRIDONES; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84893636411     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30878-6     Document Type: Editorial

References (14)

1. Landells LJ, Naidoo B, Robertson J, Clark P. NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis. Lancet Respir Med 2013; 1: 191-2.
2. Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V, Armendariz-Borunda J. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 2012; 678:71-7.
3. Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-5.
4. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One 2012; 7: e47024.
5. Klein R. A new paradigm for funding medical research. Stem Cells Transl Med 2012; 1: 3-5.
6. Puggal MA, Schully SD, Srinivas PR, Papanicolaou GJ, Jaquish CE, Fabsitz RR. Translation of genetics research to clinical medicine: the national heart, lung, and blood institute perspective. Circ Cardiovasc Genet 2013;6:634-639.
7. Garattini S, Bertele V. Efficacy, safety, and cost of new anticancer drugs. Bmj 2002; 325: 269-71.
8. Apolone G. Clinical and outcome research in oncology. The need for integration. Health Qual Life Outcomes 2003; 1: 3.
9. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: metaepidemiological study. Bmj 2013; 346: f2304.
10. Inthout J, Ioannidis JP, Borm GF. Obtaining evidence by a single well-powered trial or several modestly powered trials. Stat Methods Med Res 2012; Oct 14. [Epub ahead of print].
11. Oberfeld D, Franke T. Evaluating the robustness of repeated measures analyses: the case of small sample sizes and nonnormal data. Behav Res Methods 2013; 45: 792-812.
12. Mendez-Sanchez N, Garcia-Villegas E, Merino-Zeferino B, Ochoa-Cruz S, Villa AR, Madrigal H, et al. Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. Ann Hepatol 2010; 9: 428-38.
13. Ledford H. Pharma scrambles to fast-track drugs. Nature 2013; 502: 20.
14. Rich EC. From methods to policy: Primum non nocere: reconciling patient-centered outcomes with evidence-based care. J Comp Eff Res 2013; 2: 107-8.